HLX-22
Based on 1 Customer Validation
HLX-22 is a humanized monoclonal antibody targeting HER2. HLX-22 induces apoptosis in HER2-overexpressing breast and gastric cancer cells combined with Trastuzumab (HY-P9907). HLX-22 has potent antitumor activity against advanced solid tumors.
For research use only. We do not sell to patients.
- Purity : 99.47%
- CAS No.: 2851060-90-5
- Molecular Weight:144.18 kDa
-
Storage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
HER2 |
In Vitro
Combined treatment with HLX22 and Trastuzumab (HY-P9907) inhibits growth and enhances apoptosis in HER2-overexpressing breast cancer cells and gastric cancer cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Application
ELISA, FACS, Functional assay
Product Details
-
CAS No. 2851060-90-5
-
Accession P04626
-
Synonyms AC101
-
Molecular Weight 144.18 kDa
-
Species Reactivity
Human
-
Conjugated
Unconjugated
-
Isotype
Human IgG1 kappa
-
Recommend Isotype Controls
Product Properties
-
Appearance
Liquid
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Purity
99.47%
-
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
-
Storage & Stability
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Shipping
Shipping with dry ice.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- HLX-22
- 2851060-90-5
- AC101
- HLX22
- HLX 22
- AC 101
- AC-101
- EGFR
- Apoptosis
- Epidermal growth factor receptor
- ErbB-1
- HER1
- XELOX
- HER2-overexpressing solid tumors
- HER2
- HER2-overexpressing breast cancer cells
- trastuzumab
- HER2-positive advanced gastric/gastroesophageal junction cancer
- HLX02
- gastric cancer cells
- Inhibitor
- inhibitor
- inhibit